Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Sales | 1,032,336 | 580,415 | 1,211,975 | 1,527,042 | 1,410,626 |
| Cost of Goods | 124,512 | 60,987 | 130,277 | 279,885 | 80,505 |
| Gross Profit | 907,824 | 519,428 | 1,081,698 | 1,247,157 | 1,330,121 |
| Operating Expenses | 1,375,215 | 1,212,827 | 1,691,983 | 1,201,315 | 1,216,806 |
| Operating Income | -466,879 | -692,412 | -610,008 | 46,727 | 113,820 |
| Interest Expense | 84,206 | 72,863 | 22,926 | 15,040 | 37,681 |
| Other Income | -6,715 | 30,400 | 6,890 | 309 | -15,694 |
| Pre-tax Income | -557,800 | -734,875 | -626,044 | 31,996 | 60,445 |
| Income Tax | 30,381 | 6,958 | -122,422 | -275 | 19,266 |
| Net Income Continuous | -588,181 | -741,833 | -503,622 | 32,271 | 41,179 |
| Net Income Discontinuous | N/A | -912 | -183,928 | -83,406 | N/A |
| Minority Interests | -31,847 | -4,190 | -242,522 | 55,897 | 11,605 |
| Net Income | $-556,334 | $-738,555 | $-445,028 | $-107,032 | $29,574 |
| EPS Basic Total Ops | -2.31 | -3.14 | -1.98 | -0.50 | 0.14 |
| EPS Basic Continuous Ops | -2.44 | -3.14 | -2.24 | 0.15 | 0.20 |
| EPS Basic Discontinuous Ops | N/A | 0.00 | 0.26 | -0.65 | N/A |
| EPS Diluted Total Ops | -2.31 | -3.14 | -1.98 | -0.50 | 0.14 |
| EPS Diluted Continuous Ops | -2.44 | -3.14 | -2.24 | 0.15 | 0.20 |
| EPS Diluted Discontinuous Ops | N/A | 0.00 | 0.26 | -0.65 | N/A |
| EBITDA(a) | $-404,536 | $-629,155 | $-561,643 | $84,918 | $148,861 |